Guardant Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on March 22, 2024, reporting events occurring on March 18, 2024. The filing addresses Item 5.02 regarding the appointment of certain officers and their compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
Material Changes
On March 18, 2024, the Board approved new Letter Agreements with co-CEOs Helmy Eltoukhy and AmirAli Talasaz, effective January 1, 2024. Key changes include:
- Base Salary: Remains at $1 annually.
- Annual Awards: Commencing in 2024, each co-CEO receives RSUs and PSUs with a combined dollar-denominated value of $800,000 in lieu of base salary and cash bonuses.
- 2024 Long-Term Awards: Each co-CEO receives RSUs and PSUs with a combined dollar-denominated value of $5,000,000.
- Performance Metrics: PSUs are tied to Revenue CAGR and Total Shareholder Return (TSR) goals over a three-year period beginning January 1, 2025.
- Previous Awards: PSU awards granted on May 26, 2020, were cancelled in connection with this agreement.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed relates to the significant equity-based compensation structure, which ties executive retention and rewards to future revenue growth and stock performance targets.
Investor Verification Checklist
- Verify the specific vesting schedules for the $5,000,000 long-term awards in the full Letter Agreement (Exhibit 10.1).
- Confirm the specific Revenue CAGR and TSR targets defined for the 2025-2027 performance period.
- Review the impact of the cancelled 2020 PSU awards on total executive compensation expense.
- Assess the dilution impact of the new $5.8 million per executive equity grants on existing shareholders.